New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Clinuvel Pharmaceuticals Ltd. - Sponsored ADR (CUVL) vs Ocugen, Inc. (OCGN)

Clinuvel Pharmaceuticals Ltd. - Sponsored ADR and Ocugen, Inc. are both Biotechnology companies. Clinuvel Pharmaceuticals Ltd. - Sponsored ADR and Ocugen, Inc. are of similar size ($248.6M and $237.8M). Across the 1 metrics below, Clinuvel Pharmaceuticals Ltd. - Sponsored ADR leads on 1 and Ocugen, Inc. on 0.

Valuation

Metric CUVL OCGN Biotechnology median
P/E — n/m 8.49
P/S — 54.65 8.56
P/B — n/m 2.04
Price to free cash flow — n/m 23.84
EV/EBITDA — n/m 0.69
EV/Sales — 37.40 8.00
Earnings yield — (25.97%) (35.81%)
Free cash flow yield — (24.47%) (25.41%)

Profitability

Metric CUVL OCGN Biotechnology median
Gross margin — 100.00% 70.18%
Operating margin — (1,444.47%) 0.00%
Net margin — (1,367.61%) 0.00%
Free cash flow margin — (1,337.16%) 0.00%
Return on equity — 923.92% (51.58%)
Return on assets — (78.91%) (45.91%)
Return on invested capital — 0.00% 0.00%

Growth

Metric CUVL OCGN Biotechnology median
Revenue growth (TTM) — (11.01%) 7.20%
EPS growth (last fiscal year) (2.13%) (15.00%) 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric CUVL OCGN Biotechnology median
Debt to equity — (0.10) 0.00
Current ratio — 0.77 4.79
Net debt to EBITDA — (0.17) 1.01

Dividend

Metric CUVL OCGN Biotechnology median
Dividend yield 0.62% — 0.41%
Payout ratio — — —

Size

Metric CUVL OCGN Biotechnology median
Market cap 237.81m 248.64m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack